Artivion (AORT) Projected to Post Quarterly Earnings on Thursday

Artivion (NYSE:AORT) is projected to post its quarterly earnings results after the market closes on Thursday, February 20th. Analysts expect Artivion to post earnings of $0.12 per share and revenue of $100.82 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Artivion Stock Performance

Artivion stock opened at $29.93 on Wednesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. Artivion has a 1-year low of $18.38 and a 1-year high of $32.33. The firm has a market capitalization of $1.25 billion, a P/E ratio of -1,496.50 and a beta of 1.75. The company’s 50-day moving average is $29.80 and its 200 day moving average is $27.70.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Oppenheimer increased their price objective on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. JMP Securities reissued a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research report on Tuesday, December 10th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $34.00 price objective on shares of Artivion in a research report on Tuesday, January 28th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Artivion presently has a consensus rating of “Buy” and a consensus price target of $31.80.

Insider Activity

In other news, CAO Amy Horton sold 4,329 shares of Artivion stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $29.66, for a total transaction of $128,398.14. Following the completion of the sale, the chief accounting officer now owns 135,660 shares of the company’s stock, valued at approximately $4,023,675.60. The trade was a 3.09 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Jean F. Holloway sold 8,070 shares of Artivion stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $30.12, for a total transaction of $243,068.40. Following the sale, the senior vice president now directly owns 153,862 shares of the company’s stock, valued at $4,634,323.44. This represents a 4.98 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 20,017 shares of company stock valued at $600,007. Corporate insiders own 8.10% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.